Selected research
Industry Research
Antisense Oligonucleotide Therapies Industry Research Report 2026
Market perspective
The global Antisense Oligonucleotide Therapies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Antisense Oligonucleotide Therapies market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antisense Oligonucleotide Therapies market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antisense Oligonucleotide Therapies market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antisense Oligonucleotide Therapies include Sarepta Therapeutics, Nippon Shinyaku and Ionis Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Antisense Oligonucleotide Therapies market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antisense Oligonucleotide Therapies.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antisense Oligonucleotide Therapies Market by Company
Sarepta Therapeutics
Nippon Shinyaku
Ionis Pharmaceuticals
Antisense Oligonucleotide Therapies Segment by Type
Without GalNAc-conjugated
With GalNAc-conjugated
Antisense Oligonucleotide Therapies Segment by Application
Cancer
Cardiovascular Diseases
Genetic Disease
Other
Antisense Oligonucleotide Therapies Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense Oligonucleotide Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antisense Oligonucleotide Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense Oligonucleotide Therapies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antisense Oligonucleotide Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Without GalNAc-conjugated
- With GalNAc-conjugated
Applications
- Cancer
- Cardiovascular Diseases
- Genetic Disease
- Other
Companies covered
- Sarepta Therapeutics
- Nippon Shinyaku
- Ionis Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Antisense Oligonucleotide Therapies by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Without GalNAc-conjugated
- 2.2.3 With GalNAc-conjugated
- 2.3 Antisense Oligonucleotide Therapies by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Cardiovascular Diseases
- 2.3.4 Genetic Disease
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Antisense Oligonucleotide Therapies Breakdown Data by Type
- 3.1 Global Antisense Oligonucleotide Therapies Historic Market Size by Type (2021-2026)
- 3.2 Global Antisense Oligonucleotide Therapies Forecasted Market Size by Type (2027-2032)
4 Antisense Oligonucleotide Therapies Breakdown Data by Application
- 4.1 Global Antisense Oligonucleotide Therapies Historic Market Size by Application (2021-2026)
- 4.2 Global Antisense Oligonucleotide Therapies Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Antisense Oligonucleotide Therapies Market Perspective (2021-2032)
- 5.2 Global Antisense Oligonucleotide Therapies Growth Trends by Region
- 5.2.1 Global Antisense Oligonucleotide Therapies Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Antisense Oligonucleotide Therapies Historic Market Size by Region (2021-2026)
- 5.2.3 Antisense Oligonucleotide Therapies Forecasted Market Size by Region (2027-2032)
- 5.3 Antisense Oligonucleotide Therapies Market Dynamics
- 5.3.1 Antisense Oligonucleotide Therapies Industry Trends
- 5.3.2 Antisense Oligonucleotide Therapies Market Drivers
- 5.3.3 Antisense Oligonucleotide Therapies Market Challenges
- 5.3.4 Antisense Oligonucleotide Therapies Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Antisense Oligonucleotide Therapies Players by Revenue
- 6.1.1 Global Top Antisense Oligonucleotide Therapies Players by Revenue (2021-2026)
- 6.1.2 Global Antisense Oligonucleotide Therapies Revenue Market Share by Players (2021-2026)
- 6.2 Global Antisense Oligonucleotide Therapies Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Antisense Oligonucleotide Therapies Head Office and Area Served
- 6.4 Global Antisense Oligonucleotide Therapies Players, Product Type & Application
- 6.5 Global Antisense Oligonucleotide Therapies Manufacturers Established Date
- 6.6 Global Antisense Oligonucleotide Therapies Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Antisense Oligonucleotide Therapies Market Size (2021-2032)
- 7.2 North America Antisense Oligonucleotide Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
- 7.4 North America Antisense Oligonucleotide Therapies Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Antisense Oligonucleotide Therapies Market Size (2021-2032)
- 8.2 Europe Antisense Oligonucleotide Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
- 8.4 Europe Antisense Oligonucleotide Therapies Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Antisense Oligonucleotide Therapies Market Size (2021-2032)
- 9.2 Asia-Pacific Antisense Oligonucleotide Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Antisense Oligonucleotide Therapies Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Antisense Oligonucleotide Therapies Market Size (2021-2032)
- 10.2 South America Antisense Oligonucleotide Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
- 10.4 South America Antisense Oligonucleotide Therapies Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Antisense Oligonucleotide Therapies Market Size (2021-2032)
- 11.2 Middle East & Africa Antisense Oligonucleotide Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sarepta Therapeutics
- 12.1.1 Sarepta Therapeutics Company Information
- 12.1.2 Sarepta Therapeutics Business Overview
- 12.1.3 Sarepta Therapeutics Revenue in Antisense Oligonucleotide Therapies Business (2021-2026)
- 12.1.4 Sarepta Therapeutics Antisense Oligonucleotide Therapies Product Portfolio
- 12.1.5 Sarepta Therapeutics Recent Developments
- 12.2 Nippon Shinyaku
- 12.2.1 Nippon Shinyaku Company Information
- 12.2.2 Nippon Shinyaku Business Overview
- 12.2.3 Nippon Shinyaku Revenue in Antisense Oligonucleotide Therapies Business (2021-2026)
- 12.2.4 Nippon Shinyaku Antisense Oligonucleotide Therapies Product Portfolio
- 12.2.5 Nippon Shinyaku Recent Developments
- 12.3 Ionis Pharmaceuticals
- 12.3.1 Ionis Pharmaceuticals Company Information
- 12.3.2 Ionis Pharmaceuticals Business Overview
- 12.3.3 Ionis Pharmaceuticals Revenue in Antisense Oligonucleotide Therapies Business (2021-2026)
- 12.3.4 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product Portfolio
- 12.3.5 Ionis Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst